Medsafe Datasheet
ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
Vaccine Schedule
Recommended on the New Zealand Immunisation Schedule at 45 and 65 years of age.
Recommended and offered free on the New Zealand Immunisation Catch Up Schedule to children from 7 years of age and NZ resident adults who have not completed their primary course of three tetanus and diphtheria vaccinations.
Who should get the vaccine
All adults at risk of coming in contact with tetanus spores and/or diphtheria bacterium.
Children from 7 years of age and adults who have a tetanus prone wound AND who have not had a tetanus containing vaccination in the previous 5 years.
Who should not get the vaccine
Anyone with severe allergy (anaphylaxis) to a previous dose of this vaccine; a previous dose of diphtheria or tetanus vaccine or a component of the vaccine.
Administration of ADT™ Booster should be postponed in individuals suffering from a fever over 38°C. The presence of a minor infection is not a reason to delay immunisation.
How effective is the vaccine
-
ADT™ Booster is licensed as a booster vaccine and effectively increases a person’s existing immunity to tetanus and diphtheria
-
There is no published information on the effectiveness of ADT™ Booster when it is used for a primary immunisation course. However, based on the general principles of the human immune response to vaccination, a primary course of three ADT™ Booster vaccines is expected to result in protection from tetanus and diphtheria.
How safe is the vaccine?
For all vaccines, similar to most medications, an extremely rare allergic reaction called ‘anaphylaxis’ can occur. Anaphylaxis after immunisation occurs about 1-3 times in every one million vaccine doses. All vaccinators will have training and equipment to deal with this situation in the unlikely event of it occurring. No other serious responses to the vaccine have been identified.
What if my child misses a dose?
Children from 7 years of age and adults can catch up missed doses of this vaccine anytime.
Recommendations
ADT™ Booster is recommended and offered free to New Zealand resident adults who have not completed their primary course of three tetanus and diphtheria vaccinations. ADT™ Booster is not licensed for use as a primary series. However, there is no alternative non-booster strength vaccine available for adults and no safety concerns are expected when it is used in a primary course.
| Possible vaccine side effects |
| Common side effects | Uncommon side effects | Rare/very rare side effects |
Soreness/pain, redness and/or swelling around the injection site. Local reactions generally increase with the number of doses given. Fever above 38°C. Malaise. | Redness and/or swelling more than 6 cm in size around the injection site.
In a small percentage of vaccine recipients the reactions will be severe enough to limit movement of the arm and may last for about a week. | Anaphylaxis. Urticaria. Inflammation of the nerve in the arm causing muscle weakness and pain (brachial neuritis) occurs within four weeks of immunisation, 1- 2 times per 200,000 doses. It may occur in either the injected or non-injected arm. Recovery is spontaneous and usually without long term consequences. Granuloma or sterile abscess at the injection site. High fever over 40°C. |
References
CSL Biotherapies (NZ) Ltd. ADT Booster data sheet [Home page on the Internet]. Wellington: Medsafe; 2010 [cited 2011, May 16]. Available from: http://www.medsafe.govt.nz/profs/Datasheet/a/ADTBoosterinj.pdf.
CSL Limited. ADT Booster product information [Home page on the Internet]. Woden, A.C.T.: Therapeutic Goods Administration; 2010 [cited 2011, June 4]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06016-3.
Medical Advisory Committee of Haemophilia Foundation of New Zealand. National guidelines management of haemophilia - treatment protocols. Christchurch: Haemophilia Foundation of New Zealand; 2005.
Ministry of Health. Immunisation handbook 2011. Wellington: Ministry of Health; 2011.
Other Vaccine Brands
Dosage and Administration
ADT™ Booster is the only funded diphtheria and tetanus vaccine for adults and children aged 7 years and over, with the exception of the 11 year old schedule Boostrix® (Tdap) dose.
The primary immunisation schedule for children, 7 years of age and over, and adults consists of three doses of ADT™ Booster by deep intramuscular injection.
ADT™ Booster is licensed as a booster vaccine. It is used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups.
When the vaccine is used for a primary vaccination course use will be outside of current licensure and individuals need to be advised of this. No safety concerns are expected with use in these circumstances.
The deltoid muscle is the preferred injection site.
ADT™ Booster should be administered to children and adults with thrombocytopenia or bleeding disorders, e.g. haemophilia, in accordance with their haematologist's instructions. The vaccine may be given subcutaneously if the person's haematologist has advised against intramuscular injection of immunisations. Firm pressure should be applied to the injection site (without rubbing) for at least ten minutes following either intramuscular or subcutaneous injection.
Women who are breast feeding can safely have ADT™ Booster. No adverse consequences for a breast feeding infant have been observed following vaccination of lactating women.
ADT™ Booster can be administered concurrently with other vaccines, including all the National Immunisation Schedule vaccines. Separate syringes and different injection sites should be used.
Store between +2°C to +8°C.
The expiry date of the vaccine is the last day of the month in the year indicated on the packaging.
Efficacy/Effectiveness
When ADT™ Booster is administered to an individual who has previously completed a three dose primary course of tetanus and diphtheria immunisations protection against tetanus and diphtheria is increased.
There is no published information on the effectiveness of ADT™ Booster when it is used for a primary vaccination course. However, based on the general principles of the human immune response to vaccination, a primary course of three ADT™ Booster vaccines is expected to result in protection from tetanus and diphtheria.
Catch-Up
Refer to the catch up section of the current Immunisation Handbook for age appropriate catch up schedules.
Contraindications
A severe allergy (anaphylaxis) to a previous dose of this vaccine; a previous dose of diphtheria or tetanus vaccine or a component of the vaccine or a component of the vaccine.
Administration of ADT™ Booster should be postponed in individuals suffering from acute severe febrile illness (fever over 38°C).
The presence of a minor infection is not a contraindication.
Printer-friendly version
Send via email
